Literature DB >> 11727385

Primary chronic sclerosing (Garré's) osteomyelitis in children.

E Segev1, S Hayek, F Lokiec, E Ezra, J Issakov, S Wientroub.   

Abstract

Three children with unifocal nonpyogenic inflammatory bony lesions with a prolonged, fluctuating course are reported. The lesions were located at the metaphyseal region of long bones. Three was progressive sclerosis and hyperostosis in the tibia or femur, such as the changes described in Garré's osteomyelitis. No pus was released by exploration of the lesions. Tissue and blood cultures were negative. The histology was typical of chronic osteomyelitis: the symptoms returned intermittently over several years, together with the development of sclerosis but without disturbance of bone growth. It is not clear whether Garré's chronic sclerosing osteomyelitis is a different entity from chronic recurrent multifocal osteomyelitis.

Entities:  

Mesh:

Year:  2001        PMID: 11727385

Source DB:  PubMed          Journal:  J Pediatr Orthop B        ISSN: 1060-152X            Impact factor:   1.041


  5 in total

1.  A rare case: sclerosing osteomyelitis of the frontal bone.

Authors:  Cihan Adanas; Sezai Özkan; Abdurrahman Aycan; Remzi Erten
Journal:  Childs Nerv Syst       Date:  2019-05-26       Impact factor: 1.475

2.  Addenda.

Authors:  Armin Hofmaier
Journal:  Dtsch Arztebl Int       Date:  2022-06-07       Impact factor: 8.251

3.  SAPHO osteomyelitis and sarcoid dermatitis in a patient with DiGeorge syndrome.

Authors:  Harumi Jyonouchi; Kenneth W Lien; Helen Aguila; Gaetano G Spinnato; Sanjeev Sabharwal; Beth A Pletcher
Journal:  Eur J Pediatr       Date:  2006-02-21       Impact factor: 3.183

4.  Chronic Recurrent Multifocal Osteomyelitis Mimicking Osteosarcoma.

Authors:  Jesse D Bracamonte; Catherine C Roberts
Journal:  Radiol Case Rep       Date:  2015-11-06

5.  A 53-year-old man with a sclerosing rib lesion: A case report.

Authors:  Shucai Bai; Huafeng Zhang; Zhijun Li; Dong Li; Hui Li
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.